ATE387629T1 - Gemeinsame epitope von antigenen aus einer multigen-familie - Google Patents

Gemeinsame epitope von antigenen aus einer multigen-familie

Info

Publication number
ATE387629T1
ATE387629T1 AT03732631T AT03732631T ATE387629T1 AT E387629 T1 ATE387629 T1 AT E387629T1 AT 03732631 T AT03732631 T AT 03732631T AT 03732631 T AT03732631 T AT 03732631T AT E387629 T1 ATE387629 T1 AT E387629T1
Authority
AT
Austria
Prior art keywords
antigens
epitopes
common
common epitopes
amino acids
Prior art date
Application number
AT03732631T
Other languages
English (en)
Inventor
Kostas Kosmatopoulos
Stephanie Graff-Dubois
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE387629T1 publication Critical patent/ATE387629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03732631T 2002-03-28 2003-03-27 Gemeinsame epitope von antigenen aus einer multigen-familie ATE387629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203888A FR2837837B1 (fr) 2002-03-28 2002-03-28 Epitopes peptidiques communs a des antigenes d'une meme famille multigenique

Publications (1)

Publication Number Publication Date
ATE387629T1 true ATE387629T1 (de) 2008-03-15

Family

ID=27839271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03732631T ATE387629T1 (de) 2002-03-28 2003-03-27 Gemeinsame epitope von antigenen aus einer multigen-familie

Country Status (10)

Country Link
US (1) US7419669B2 (de)
EP (1) EP1485719B1 (de)
AT (1) ATE387629T1 (de)
AU (1) AU2003239659A1 (de)
CA (1) CA2480696C (de)
DE (1) DE60319350T2 (de)
ES (1) ES2301800T3 (de)
FR (1) FR2837837B1 (de)
PT (1) PT1485719E (de)
WO (1) WO2003083124A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE557099T1 (de) 2003-09-05 2012-05-15 Genencor Int Hpv cd8+ t-zell-epitope
CA2606871C (en) * 2005-05-09 2014-06-03 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
AU2006321593B2 (en) * 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
PT2440575E (pt) * 2009-06-09 2015-02-12 Vaxon Biotech Identificação, optimização e utilização de epitopos hla-b*0702 partilhados para imunoterapia
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
EP2760892A1 (de) 2011-09-29 2014-08-06 Apo-T B.V. Multispezifische bindungsmoleküle zur anzielung aberranter zellen
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2013177214A2 (en) * 2012-05-21 2013-11-28 Distributed Bio Inc Epitope focusing by variable effective antigen surface concentration
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP6255360B2 (ja) * 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
EP4434589A3 (de) 2015-10-23 2025-05-14 President and Fellows of Harvard College Entwickelte cas9-proteine für geneditierung
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
WO2001041787A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CA2393339A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
EP1485719A2 (de) 2004-12-15
EP1485719B1 (de) 2008-02-27
US20060263381A1 (en) 2006-11-23
FR2837837A1 (fr) 2003-10-03
US7419669B2 (en) 2008-09-02
CA2480696A1 (fr) 2003-10-09
WO2003083124A2 (fr) 2003-10-09
PT1485719E (pt) 2008-05-02
DE60319350T2 (de) 2009-03-26
AU2003239659A1 (en) 2003-10-13
ES2301800T3 (es) 2008-07-01
DE60319350D1 (de) 2008-04-10
AU2003239659A8 (en) 2003-10-13
WO2003083124A3 (fr) 2004-04-01
CA2480696C (fr) 2012-10-16
FR2837837B1 (fr) 2006-09-29

Similar Documents

Publication Publication Date Title
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
NO20063026L (no) Antistoffer
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
EA200870237A1 (ru) Последовательности пептидов и композиции
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
WO2006076410A3 (en) Li-key/antigenic epitope hybrid peptide vaccines
DE69733823D1 (de) GnRH-LEUKOTOXIN-CHIMÄRE
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ATE435870T1 (de) Aus ll-37 abgeleiteten peptidinhibitoren von toxinen
CY1111630T1 (el) Παραγωγα κυτοκινων
DK1370284T3 (da) Bakteriofag-medieret immunisering
TW200608990A (en) Cetp-vaccines
TW200505943A (en) Polypeptide
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
WO2006090090A3 (fr) Epitopes de vih et composition pharmaceutique les contenant
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
DK1913020T3 (da) Immunogene konstrukter
DK1614690T3 (da) Peptidfragment af LYVE-1 og antistof mod dette
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2010088393A3 (en) Li-kay hybrid peptides that modulate the immune response to influenza
SE0101519D0 (sv) Nucleic ACID
GB0222824D0 (en) Bacteriophage-mediated immunisation II

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1485719

Country of ref document: EP